Photo from researchgate.net
Jun 27, 2023, 18:43
A cheaper and effective approach to clinical CAR-T manufacturing
In as post by Since joining Crystal Mackall lab, Hyatt Balke-Want wanted to develop a robust viral-free platform that would yield enough CAR-T cells to treat patients. Under the expert eye of Steven Feldman he developed HITI, a system based on nanoplasmid DNA to specifically knock-in CAR via homology-independent targeted insertion, together with a selection marker. Upon enrichment of the engineered population, he achieved ~80% pure CAR-T cells at doses therapeutically relevant and without any evidence of off-target genomic toxicity.
A cheaper and effective approach to clinical CAR-T manufacturing!”
For details: Click here
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 27, 2025, 17:56
Feb 27, 2025, 17:55
Feb 27, 2025, 17:54
Feb 27, 2025, 17:53
Feb 27, 2025, 17:49
Feb 27, 2025, 17:46
Feb 27, 2025, 17:13
Feb 27, 2025, 17:10